|
Dear CCPA Purchasing Partners Members,
Please be reminded that the deadline to create, adjust, and/or confirm your Sanofi Pasteur Fluzone reservation is March 31, 2015!
For questions regarding Sanofi Pasteur's Fluzone vaccine products and/or the Fluzone dose reservation process, please contact your Sanofi Pasteur Vaccine Representative or call Sanofi Pasteur at 800.VACCINE (800.822.2463). For any further questions or for your practice's username and/or password to log on to our site, please contact Priya Stemler, Director of Operations for CCPAPP, at 312.227.7437 or pstemler@ccpapp.org.
Thank you for your continued participation in CCPA Purchasing Partners and in the Sanofi Pasteur-CCPAPP agreement!
Sincerely,
CCPA Purchasing Partners, L.P.
2015-2016 Fluzone Vaccine Partners Program:
|
Promotional Discount
|
Members who confirm Fluzone vaccine reservation by March 31, 2015 are eligible for a 3% promotional discount on all presentations of Fluzone vaccine excluding
Fluzone Quadrivalent vaccine 0.25 mL syringes (pediatric dose) and Fluzone High-Dose vaccine
| |
Payment Terms
|
2% 90; net 91 days
| |
Shipping Visibility
|
Up to 6 weeks visibility of future shipments
| |
Delivery Terms For All Presentations Except Fluzone High-Dose Vaccine
|
QIV PFS, UDV, and Ped presentations of Fluzone vaccine confirmed by March 31,2015*:
10% by August 31, 2015
50% by September 30, 2015
90% by October 31, 2015
100% by November 15, 2015
______________________________________________________________
MDV and ID presentations of Fluzone vaccine confirmed by March 31,2015*:
15% by August 31, 2015
100% by September 30, 2015
| |
Delivery Terms for Fluzone High-Dose Vaccine Only
|
Fluzone High-Dose vaccine confirmed by March 31, 2015*:
20% by August 31,2015
75% by September 30,2015
100% by mid-October 2015
| |
End of Season
Performance Credit
|
By retaining a minimum of 90% of prior year Fluzone vaccine doses, members may earn a 2% credit on Fluzone Quadrivalent vaccine 0.25mL syringes (pediatric dose) and Fluzone High-Dose vaccine
| |
Risk Sharing
|
25% if shipped before or on October 31,2015
50% if shipped after October 31, 2015
Returns accepted upon expiration and must be received by August 31st
| |
VaxMax
|
Additional 1% discount on VaxMax-eligible vaccines
|
* Modifications made after March 31,2015 to confirmed Fluzone reservations will not be eligible for shipping guarantees
Reservation Process:
For CCPAPP members who are currently enrolled in Sanofi Pasteur's Recurring Reservation program, your 2015-2016 Fluzone vaccine reservation has already been created for you. You will need to complete the reservation process by following the 3 steps below:
- Step 1: Log onto www.vaccineshoppe.com and go to the Fluzone tab or call 1-800-VACCINE (1-800-822-2463) by March 31, 2015.
- Step 2: Review or adjust your reservation as needed (you may increase or decrease quantities or change presentations of your Fluzone vaccine reservation).
- Step 3: Review/update your contact information and delivery hours (if needed) and your reservation is confirmed!
If you are not currently enrolled in Sanofi Pasteur's Recurring Reservation Program, you have until March 31, 2015 to create your reservation.
Information about Fluzone Products
You can learn more about each Fluzone product on the Sanofi Pasteur website (click on each of the product names below):
Fluzone
Fluzone Intradermal
(Be sure to view the short video clip, showing how Fluzone Intradermal works and how to administer the vaccine). Fluzone High-Dose
Full Prescribing information for Fluzone products can be viewed by clicking on each of the following:
Fluzone Full Prescribing Information
Fluzone Quadrivalent Full Prescribing Information
Fluzone Intradermal Full Prescribing Information
Fluzone High-Dose Full Prescribing Information
The Prescribing Information for Fluzone High-Dose vaccine has been updated to include results from the Fluzone High-Dose vaccine efficacy trial. The efficacy results showed that Fluzone High-Dose vaccine was 24.2% more effective at preventing protocol-defined, laboratory-confirmed influenza disease in adults 65 years of age and older compared to Fluzone vaccine. This primary endpoint result reflects all infecting influenza strains, regardless of type or similarity to the strains in the vaccine. A secondary endpoint for the efficacy trial showed that Fluzone High-Dose vaccine was 51.1% more effective at preventing modified CDC-defined, culture-confirmed influenza disease in adults 65 years of age and older compared to Fluzone vaccine against strains that were antigenically similar to those found in the vaccine.
| 
